- Home
- IVVD vs SST Comparison
IVVD vs SST Comparison
Compare IVVD & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVVD | SST |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.7M | 67.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IVVD | SST |
|---|---|---|
| Price | $2.22 | $3.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $8.33 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 12.0M | 24.5K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $50,039,000.00 | ★ $289,784,000.00 |
| Revenue This Year | $103.88 | N/A |
| Revenue Next Year | $171.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 332.71 | N/A |
| 52 Week Low | $0.35 | $2.90 |
| 52 Week High | $3.07 | $15.00 |
Technical Indicators
Market Signals| Indicator | IVVD | SST |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 40.41 |
| Support Level | $2.09 | $3.54 |
| Resistance Level | $2.60 | $4.01 |
| Average True Range (ATR) | 0.25 | 0.39 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 13.27 | 66.99 |
Price Performance
Historical ComparisonAbout IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.